- €2.57m
- €19.17m
- €33.25m
Brief: Paion FY revenues up at 4.3 million euros
Brief: Paion to issue about 2.4 mln shares at EUR 2.05 per share
Brief: Paion: clinical development progress with remimazolam in China by partner Yichang Humanwell
Brief: PAION completes patient recruitment in U.S. clinical safety trial of remimazolam
Brief: Paion 9-month net loss narrows to 16.06 million euros
Brief: Paion presents positive remimazolam phase III colonoscopy results
Brief: Paion announces clinical development progress with remimazolam by its partner Yichang Humanwell
Brief: Paion H1 net loss widens to 13.2 million euros
Brief: Paion completes private placement of 9.6 million euros
Brief: Paion, unit of Cosmo Pharmaceuticals enter into license deal for Remimazolam
Brief: Paion reports positive remimazolam headline data in phase III study in procedural sedation for colonoscopy
Brief: Paion Q1 net loss widens to 6.73 million euros
Brief: Paion completes patient recruitment in phase III study with Remimazolam
Brief: Paion FY net loss of 28.2 mln euros in line with its guidance
Brief: Paion gets positive feedback from Japanese authority PMDA for filing of Remimazolam in Japan
Brief: Paion US-patent & trademark office grants substance patent for Remimazolam Besylate
Brief: Paion discontinues European Remimazolam Phase 3 trial
Brief: Paion: initiation of Remimazolan U.S. clinical safety trial in patiens undergoing colonoscopy
Brief: Paion 9-mth net loss widens to EUR 20.4 mln